Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer

Can stereotactic body radiotherapy (SBRT) be delivered safely and effectively as a single fraction of 19 Gy for patients with localized prostate cancer?In this phase 1/2 nonrandomized clinical trial including 45 patients with localized prostate cancer, the primary hypothesis was confirmed, with the estimated 3-year biochemical relapse-free survival meeting the predefined primary end point. Treatment was well tolerated, and treatment-related adverse events as well as quality-of-life outcomes assessed over the first 3 years demonstrated the safety and good tolerability of single-fraction SBRT.These results suggest that single-fraction SBRT is a feasible and well-tolerated treatment strategy that warrants further investigation as a potential option for carefully selected patients with localized prostate cancer.

Corresponding Author: Thomas Zilli, MD, Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Via Ospedale, 6500 Bellinzona, Switzerland (thomas.zilli@eoc.ch).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.